+4%

est. 2Y upside i

Healthcare

Rank

#1959

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Biomodal offers a high-risk, asymmetric opportunity.

Last updated: July 3, 2026

Bull (15%)+200%

Biomodal achieves category leadership and opens an IPO window, sustaining a 15x forward multiple on $61M revenue, implying ~$915M exit. Net of 20% dilution, upside is 200% capped.

Base (40%)+47%

Multiple converges toward the public-comp range of 3-5x, settling at 6x on $61M revenue for ~$366M exit. After 20% dilution, upside is 47.2%.

Bear (45%)-100%

Exit multiple compresses to 3x ($183M), below $164M total funding. 1x non-participating preferred absorbs all proceeds, leaving common stock worth $0.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

1900%

Total funding of $164M against an assumed $200M valuation means preferred stock holds 82% of the company, leaving common stock with minimal residual value in a downside scenario.

Dilution Risk

high

With ~$8.6M revenue and high capital intensity, the company likely needs additional funding within 2 years, causing 15-25% dilution for common shareholders.

Secondary Liquidity

none

No secondary market transactions are known or implied in the data.

View all 3 open roles at biomodal →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on biomodal's data — designed to show you've done your homework.

  • 1

    “How does biomodal plan to defend its position as Illumina develops competing 5-base sequencing?”

  • 2

    “What is the unit economics and scalability of the reagent-and-kit model?”

  • 3

    “What is the company's current runway and plan for next financing round? How dilutive is it expected to be?”

Community

Valuation Sentiment

Our model estimates +4% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.